Navigation Links
MannKind to Present at the 11th Annual Biotechnology Industry Organization BIO CEO & Investor Conference

VALENCIA, Calif., Feb. 2 /PRNewswire-FirstCall/ -- MannKind Corporation (Nasdaq: MNKD), focused on discovering, developing and commercializing treatments for diabetes and cancer, announced today that it will present at the 11th Annual Biotechnology Industry Organization BIO CEO & Investor Conference on Monday, February 9, 2009 at 2:15 PM (EST) at the Hilton Waldorf Astoria in New York City. In addition to this presentation, the Company will host a breakfast meeting for invited investors and analysts at 7:30 AM (EST) on February 10th.

Interested parties can access links to live webcasts of both presentations from the News & Events section of the Company's website at Replays of the presentations will be available for 14 days.

About MannKind Corporation

MannKind Corporation (Nasdaq: MNKD) focuses on the discovery, development and commercialization of therapeutic products for patients with diseases such as diabetes and cancer. Its pipeline includes AFRESA, which has completed Phase 3 clinical trials, and MKC253, which is currently in Phase 1 clinical trials. Both of these investigational products are being evaluated for their safety and efficacy in the treatment of diabetes. MannKind maintains a website at to which MannKind regularly posts copies of its press release as well as additional information about MannKind. Interested persons can subscribe on the MannKind website to email alerts that are sent automatically when MannKind issues press releases, files its reports with the SEC or posts certain other information to the website.

SOURCE MannKind Corporation
Copyright©2009 PR Newswire.
All rights reserved

Related biology technology :

1. SemBioSys receives US$2.5 million from option agreement with MannKind for plant-produced insulin
2. MannKind to Present at the Piper Jaffray 20th Annual Health Care Conference
3. MannKind to Present at the Rodman & Renshaw Annual Global Investment Conference
4. MannKind Corporation to Hold Third Quarter Financial Results Conference Call on November 5, 2008
5. MannKind Unveils Proposed Trade Name at Dedication of Danbury Manufacturing Facility
6. MannKind to Present at the UBS Global Life Sciences Conference
7. MannKind Corporation Reports Second Quarter Financial Results
8. MannKind Corporation to Hold Second Quarter Financial Results Conference Call on August 11, 2008
9. MannKind to Present at Upcoming Conferences
10. MannKind Corporation Reports First Quarter Financial Results
11. MannKind to Present at the Morgan Stanley Healthcare Conference
Post Your Comments:
(Date:6/24/2016)... DIEGO , June 24, 2016 ... more sensitively detects cancers susceptible to PARP inhibitors ... circulating tumor cells (CTCs). The new test has ... HRD-targeted therapeutics in multiple cancer types. ... targeting DNA damage response pathways, including PARP, ATM, ...
(Date:6/23/2016)... ... June 23, 2016 , ... Mosio, ... second eBook, “Clinical Trials Patient Recruitment and Retention Tips.” Partnering with experienced clinical ... eBook by providing practical tips, tools, and strategies for clinical researchers. , “The ...
(Date:6/23/2016)... June 23, 2016 /PRNewswire/ - FACIT has announced ... biotechnology company, Propellon Therapeutics Inc. ("Propellon" ... commercialization of a portfolio of first-in-class WDR5 inhibitors ... such as WDR5 represent an exciting class of ... precision medicine for cancer patients. Substantial advances have ...
(Date:6/23/2016)... (PRWEB) , ... June 23, 2016 , ... ... Plate® YM (Yeast and Mold) microbial test has received AOAC Research Institute approval ... of microbial tests introduced last year,” stated Bob Salter, Vice President of Regulatory ...
Breaking Biology Technology:
(Date:5/20/2016)... 2016  VoiceIt is excited to announce its ... By working together, VoiceIt and VoicePass will ... VoicePass take slightly different approaches to voice biometrics, ... and usability. ... partnership. "This marketing and technology partnership ...
(Date:5/12/2016)... DALLAS , May 12, 2016 ... has just published the overview results from the Q1 ... of the recent wave was consumers, receptivity to a ... wearables data with a health insurance company. ... choose to share," says Michael LaColla , CEO ...
(Date:5/3/2016)... VILNIUS, Lithuania , May 3, 2016 /PRNewswire/ ... today released the MegaMatcher Automated Biometric Identification ... deployment of large-scale multi-biometric projects. MegaMatcher ABIS can ... and accuracy using any combination of fingerprint, face ... of MegaMatcher SDK and MegaMatcher ...
Breaking Biology News(10 mins):